Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 625 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Lung Adenocarcinoma with Mucinous Histology December 16, 2024 Increase in Node-Positive and Stage III Breast Cancer After Two Months... February 26, 2021 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 Marine Runs Five Marathons in Five Days to Help Fund Sister’s... April 20, 2021 Load more HOT NEWS 2026 Heine H. Hansen Award Recipient Announced Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells
